Literature DB >> 23255514

Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis.

Charalampos Siristatidis1, Theodoros N Sergentanis, Prodromos Kanavidis, Marialena Trivella, Marianthi Sotiraki, Ioannis Mavromatis, Theodora Psaltopoulou, Alkistis Skalkidou, Eleni Th Petridou.   

Abstract

BACKGROUND: In response to the ongoing debate on the long-term effects of assisted reproduction technologies, such as IVF, we systematically reviewed and meta-analyzed available evidence on the association between controlled ovarian hyperstimulation for IVF and risk of ovarian, endometrial and cervical cancer.
METHODS: Eligible studies were identified and pooled effect estimates for relative risk (RR) were calculated by cancer type among two reference groups (general population or infertile women), through fixed- or random-effects models as appropriate.
RESULTS: Nine cohort studies were synthesized, corresponding to a total size of 109 969 women exposed to IVF, among whom 76 incident cases of ovarian, 18 of endometrial and 207 cases of cervical cancer were studied. The synthesis of studies with general population as the reference group pointed to a statistically significant positive association between IVF and increased risk for ovarian (RR = 1.50, 95% confidence interval (CI): 1.17-1.92) and endometrial (RR = 2.04, 95% CI: 1.22-3.43), but not cervical (RR = 0.86, 95% CI: 0.49-1.49) cancers. On the contrary, when infertile women were used as the reference group, no significant associations with ovarian, endometrial or cervical cancer types were noted (RR = 1.26, 95% CI: 0.62-2.55 RR = 0.45, 95% CI: 0.18-1.14 and RR = 5.70, 95% CI: 0.28-117.20, respectively).
CONCLUSIONS: IVF does not seem to be associated with elevated cervical cancer risk, nor with ovarian or endometrial cancer when the confounding effect of infertility was neutralized in studies allowing such comparisons. Of note, only one study provided follow-up longer than 10 years for the group exposed to IVF. Future cohort studies should preferably use infertile women as the reference group, rely on IVF-registered valid exposure data, adjust for a variety of meaningful confounders and adopt relatively longer follow-up periods before sound conclusions are drawn.

Entities:  

Mesh:

Year:  2012        PMID: 23255514     DOI: 10.1093/humupd/dms051

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  44 in total

1.  Cancer in women after assisted reproductive technology.

Authors:  Barbara Luke; Morton B Brown; Logan G Spector; Stacey A Missmer; Richard E Leach; Melanie Williams; Lori Koch; Yolanda Smith; Judy E Stern; G David Ball; Maria J Schymura
Journal:  Fertil Steril       Date:  2015-08-10       Impact factor: 7.329

Review 2.  Use of fertility drugs and risk of ovarian cancer.

Authors:  Brenda Diergaarde; Michelle L Kurta
Journal:  Curr Opin Obstet Gynecol       Date:  2014-06       Impact factor: 1.927

Review 3.  Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility.

Authors:  Alkistis Skalkidou; Theodoros N Sergentanis; Spyros P Gialamas; Marios K Georgakis; Theodora Psaltopoulou; Marialena Trivella; Charalampos S Siristatidis; Evangelos Evangelou; Eleni Petridou
Journal:  Cochrane Database Syst Rev       Date:  2017-03-25

4.  Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.

Authors:  Ivana Rizzuto; Renee F Behrens; Lesley A Smith
Journal:  Cochrane Database Syst Rev       Date:  2019-06-18

Review 5.  Use of fertility medications and cancer risk: a review and update.

Authors:  Lindsay Kroener; Daniel Dumesic; Zain Al-Safi
Journal:  Curr Opin Obstet Gynecol       Date:  2017-08       Impact factor: 1.927

6.  Freeze-all cycle for all normal responders?

Authors:  Matheus Roque; Marcello Valle; Fernando Guimarães; Marcos Sampaio; Selmo Geber
Journal:  J Assist Reprod Genet       Date:  2016-11-05       Impact factor: 3.412

7.  Cancer Risk in Women Treated with Fertility Drugs According to Parity Status-A Registry-based Cohort Study.

Authors:  Marte Myhre Reigstad; Ritsa Storeng; Tor Åge Myklebust; Nan Birgitte Oldereid; Anne Katerine Omland; Trude Eid Robsahm; Louise Annette Brinton; Siri Vangen; Kari Furu; Inger Kristin Larsen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-01-20       Impact factor: 4.254

Review 8.  A Potential Pathogenic Link Between Cancer of Female Reproductive System and Infertile Women Treated With Assisted Reproduction Techniques.

Authors:  Michail Diakosavvas; Zacharias Fasoulakis; Thomas Ntounis; Antonios Koutras; Kyveli Angelou; Georgios Tsatsaris; Athanasios Syllaios; Nikolaos Garmpis; Emmanuel N Kontomanolis
Journal:  In Vivo       Date:  2021-04-28       Impact factor: 2.155

9.  Fertility outcomes in infertile women with complex hyperplasia or complex atypical hyperplasia who received progestin therapy and in vitro fertilization.

Authors:  Miao Li; Jia-Lun Song; Ying Zhao; She-Ling Wu; Hong-Bin Liu; Rong Tang; Lei Yan
Journal:  J Zhejiang Univ Sci B       Date:  2017 Nov.       Impact factor: 3.066

10.  The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up.

Authors:  R Kessous; E Davidson; M Meirovitz; R Sergienko; E Sheiner
Journal:  J Cancer Res Clin Oncol       Date:  2015-09-04       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.